Literature DB >> 17116299

5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats.

Daniela Braida1, Valeria Limonta, Lorenzo Malabarba, Alessia Zani, Mariaelvina Sala.   

Abstract

The mechanism mediating the effects of cannabinoids on anxiety-related responses appear to involve cannabinoid CB1 and non-CB1 receptors. However, other neurotransmitters may play a role in such effect. This study shows evidence of an interaction between endocannabinoid system and serotonin (5-HT), 1A receptor subtype on anxiety-like behavior in Sprague-Dawley rats. The exogenous cannabinoid agonist, Delta9-tetrahydrocannabinol (THC), and N-(4-hydroxyphenyl)-arachidonylamide, the anandamide transporter inhibitor (AM 404) were evaluated in the elevated plus maze test. THC (0.075-0.75 mg/kg i.p.), given 30 min and AM 404 (0.75-1.25 mg/kg i. p.), given 60 min before the test, exhibited a dose-response anxiolytic effect evaluated in terms of increase in the percentage of total entries and time spent in the open and decrease of total entries and time spent in the closed arms. The anxiolytic effect obtained with the maximal active dose of both THC (0.75 mg/kg) and AM 404 (1.25 mg/kg) was blocked by the 5-HT1A receptor antagonist, N-[2-[4-(2-methoxyphenyl) piperazin-1-yl]ethyl]-N-pyridin-2-yl-cyclohexanecarboxamide dihydro chloride (WAY-100635 (300 microg/kg, s.c.), given 30 min before THC or 15 min before AM 404. The combination of an ineffective dose of THC (0.015 mg/kg) or AM 404 (0.015 mg/kg) on anxiety-related responses with an ineffective dose of the 5HT(1A) receptor agonist, 8-Hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT) (7.5 microg/kg, i.p.), led to a synergistic effect. No interference with spontaneous motor activity, evaluated in an activity cage for 5 min, in rats given the drugs alone or in combination, was found. These data suggest that the anxiolytic effect produced by endo- and eso-cannabinoids is modulated by 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116299     DOI: 10.1016/j.ejphar.2006.10.038

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

3.  Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder.

Authors:  Ake T Lu; Matthew N Ogdie; Marjo-Ritta Järvelin; Irma K Moilanen; Sandra K Loo; James T McCracken; James J McGough; May H Yang; Leena Peltonen; Stanley F Nelson; Rita M Cantor; Susan L Smalley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

4.  The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System.

Authors:  Anthony L Berger; Angela M Henricks; Janelle M Lugo; Hayden R Wright; Collin R Warrick; Martin A Sticht; Maria Morena; Itziar Bonilla; Sarah A Laredo; Rebecca M Craft; Loren H Parsons; Pedro R Grandes; Cecilia J Hillard; Matthew N Hill; Ryan J McLaughlin
Journal:  Biol Psychiatry       Date:  2018-05-08       Impact factor: 13.382

Review 5.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 6.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

7.  Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.

Authors:  Emma Childs; Joseph A Lutz; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2017-05-30       Impact factor: 4.492

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 9.  Adult neurogenesis and mental illness.

Authors:  Timothy J Schoenfeld; Heather A Cameron
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

10.  Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.

Authors:  Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.